Physician profile

Annie Wu

Ophthalmology · Ann Arbor, MI

NPI 1235660549

$388.67

in general payments reported to CMS, 2019-2025

5 companies · $191 in 2025

The $191 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$248.74

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $126.00 2025 Tepezza
Sight Sciences, INC. $110.14 2021
Ani Pharmaceuticals, INC. $65.22 2025 Purified Cortrophin Gel
New World Medical,INC. $57.52 2023
Abbvie INC. $29.79 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Annie Wu

$388.67

in general payments reported 2019-2025

Years
2021-2025
Top company
Amgen INC.
Context
The $191 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).

https://glasscript.com/doctor/9114523/annie-wu

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.